Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: A randomized controlled trial

AIDS

Volumn 28, Issue 18, 2014, Pages 2701-2709

  Kamya, Moses R ^a   Kapisi, James ^b   Bigira, Victor ^b   Clark, Tamara D ^c   Kinara, Stephen ^b   Mwangwa, Florence ^b   Muhindo, Mary K ^b   Kakuru, Abel ^b   Aweeka, Francesca T ^c   Huang, Liusheng ^c   Jagannathan, Prasanna ^c   Achan, Jane ^a   Havlir, Diane V ^c   Rosenthal, Philip J ^c   Dorsey, Grant ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Dihydroartemsinin piperaquine; HIV exposed uninfected infants; Malaria chemoprevention; Sulfadoxine pyrimethamine; Trimethoprim sulfamethoxazole prophylaxis

Indexed keywords

COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PIPERAQUINE; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ANEMIA; ARTICLE; ASYMPTOMATIC INFECTION; BREAST FEEDING; CHEMOPROPHYLAXIS; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; MALE; OPEN STUDY; PARASITEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; RURAL AREA; SINGLE DRUG DOSE; TREATMENT OUTCOME; UGANDA; UGANDAN; VOMITING; ADVERSE EFFECTS; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; PRESCHOOL CHILD; PROCEDURES;

ANTIMALARIALS; ARTEMISININS; CHEMOPREVENTION; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; MALARIA; MALE; PYRIMETHAMINE; QUINOLINES; SULFADOXINE; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; UGANDA;

EID: 84924193554     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000497     Document Type: Article

References (38)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/dataanalysis/knowyourepidemic/[Accessed 25 July 2014].
2. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006; 41:504-508.
3. Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity among human immunodeficiency virusexposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J 2011; 30:45-51.
4. Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell RA. Mortality and health outcomes of HIV-exposed and unexposed children in a PMTCT cohort in Malawi. PLoS One 2012; 7:e47337.
5. Nakiyingi JS, Bracher M, Whitworth JA, Ruberantwari A, Busingye J, Mbulaiteye SM, et al. Child survival in relation to mother's HIV infection and survival: evidence from a Ugandan cohort study. AIDS 2003; 17:1827-1834.
6. Ng'weshemi J, Urassa M, Isingo R, Mwaluko G, Ngalula J, Boerma T, et al. HIV impact on mother and child mortality in rural Tanzania. J Acquir Immune Defic Syndr 2003; 33:393-404.
7. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: A growing population with a vulnerable immune system? Clin Exp Immunol 2014; 176:11-22.
8. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000; 96:3866-3871.
9. Farquhar C, Nduati R, Haigwood N, Sutton W, Mbori-Ngacha D, Richardson B, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005; 40:494-497.
10. Mazzola TN, da Silva MT, Abramczuk BM, Moreno YM, Lima SC, Zorzeto TQ, et al. Impaired Bacillus Calmette-Guerin cellular immune response in HIV-exposed, uninfected infants. AIDS 2011; 25:2079-2087.
11. Taha TE, Hoover DR, Chen S, Kumwenda NI, Mipando L, Nkanaunena K, et al. Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis 2011; 53:388-395.
12. UNICEF WHOa. Co-trimoxazole prophylaxis for HIV-exposed and HIV-infected infants and children: Practical approaches to implementation and scale up. http://www.unicef.org/aids/files/CotrimoxazoleGuide-2009.pdf. [Accessed 25 July 2014]. 2009.
13. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: A randomised trial.Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468.
14. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865- 1871.
15. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007; 21:2059-2066.
16. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21:77-84.
17. Kourtis AP, Wiener J, Kayira D, Chasela C, Ellington SR, Hyde L, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS 2013; 27:749-759.
18. Dow A, Kayira D, Hudgens M, Van Rie A, King CC, Ellington S, et al. Effects of cotrimoxazole prophylactic treatment on adverse health outcomes among HIV-exposed, uninfected infants. Pediatr Infect Dis J 2012; 31:842-847.
19. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: A prospective cohort study. Lancet 2006; 367:1256-1261.
20. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005; 192:1823-1829.
21. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya- Ntege P, Keishanyu R, Nathoo K, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014; 370:41-53.
22. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 2012; 54:1204-1211.
23. Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: A randomised clinical trial. BMJ 2011; 342:d1617.
24. WHO. Updated World Health Organization Policy Recommendation (October 2012). Intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva: WHO; 2012.
25. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: A pooled analysis of six randomised, placebo- controlled trials. Lancet 2009; 374:1533-1542.
26. WHO. World Health Organization policy recommendation on intermittent preventive treatment during infancy with sulphadoxine- pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. http://www.who.int/malaria/news/policy-recommendation-IPTi-032010/en/[Accessed 8 October 2013].
27. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005; 2:e3.
28. Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J 2014; 13:111.
29. WHO. World Health Organization (2010) WHO guidelines for the treatment of malaria. http://www.who.int/malaria/publications/atoz/9789241547925/en/[Accessed 10 April 2014].
30. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: A randomized controlled trial. PLoS Med 2014; 11:e1001689.
31. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, et al. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 2013; 207:1646-1654.
32. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012; 91:497-505.
33. Malamba S, Sandison T, Lule J, Reingold A, Walker J, Dorsey G, et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim- sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am J Trop Med Hyg 2010; 82:766-771.
34. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, Cames C, et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009; 4:e7164.
35. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: A randomized, placebo-controlled trial. Clin Infect Dis 2014; 58:1404-1412.
36. Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 2007; 4:e242.
37. Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997; 350:844-850.
38. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005; 365: 1481-1483.